Solid Tumor Clinical Trial
Official title:
A Phase 1, First-in-Human Study of IK-930, an Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors
Verified date | June 2024 |
Source | Ikena Oncology |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a Phase 1, first-in-human (FIH) clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of IK-930, an oral TEAD inhibitor, administered orally (PO) as monotherapy in subjects with advanced solid tumors with or without gene alterations in the Hippo pathway for whom there are no further treatment options known to confer clinical benefit. The study consists of two phases, an initial Dose Escalation phase followed by a Dose Expansion phase.
Status | Active, not recruiting |
Enrollment | 198 |
Est. completion date | June 2025 |
Est. primary completion date | June 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Signed informed consent must be obtained prior to participation in the study. 2. Male or female subjects = 18 years of age. 3. If feasible, subjects must be willing to consent to the submission of formalin-fixed paraffin-embedded tissue blocks or slides of tumor tissue, preferably from pre-treatment, baseline fresh tumor biopsy at Screening. Alternatively, archival tumor FFPE blocks or, unstained slides of tumor tissue from available archival sources are acceptable. 4. In the dose escalation cohort: Subjects with histologically proven advanced, unresectable, locally recurrent, or metastatic malignancy that has progressed on or following standard-of-care therapies and for whom there is no available therapy known to confer clinical benefit, regardless of the presence or absence of NF2 deficiency or other genetic alterations of the Hippo pathway. Subjects with histological confirmation of MPM; subjects with NF2-deficient MPM determined by local test results for testing can also be enrolled as well as subjects with any other solid tumors with documented NF2 deficiency determined by local test results for testing, including, but not limited to, meningioma, cholangiocarcinoma, thymoma, mucoepidermoid NSCLC, HCC, and others. Subjects diagnosed with EHE with documented TAZ-CAMTA1 or YAP1-TFE3 gene fusions, as determined by local tests and subjects with solid tumors who have YAP1/TAZ gene fusions as determined by local test results can also be enrolled in the dose escalation part of the study. 5. In the Dose expansion: Four groups of subjects will be enrolled: 1. Cohort 1: Subjects with histological confirmed MPM and that have documented NF2 deficiency, 2. Cohort 2: Subjects with other documented NF2-deficient solid tumors agnostic to tumor type including, but not limited to, meningioma, cholangiocarcinoma, thymoma, NSCLC, HCC, and others. 3. Cohort 3: Subjects with histopathological diagnosis of epithelioid hemangioendothelioma (EHE) and documented TAZ-CAMTA1 or YAP1-TFE3 gene fusions, as determined by local test results. Subjects who have objective disease progression to prior therapy or have active disease and cancer-related pain requiring narcotics for management are eligible. 4. Cohort 4: Subjects with any solid tumor with documented YAP1/TAZ gene fusions as determined by local test results. 6. In the Osimertinib Combination Cohort subjects must have a histologically proven, incurable, locally advanced or metastatic NSCLC expressing osimertinib-sensitive EGFR mutations; have evidence of radiological disease progression on prior receipt of Osimertinib and have progressed on additional anticancer therapy such as chemotherapy. 7. Subjects can have measurable or evaluable disease by RECIST 1.1 criteria as assessed by the Investigator/local radiologist. Exclusion Criteria: 1. Subjects with untreated or symptomatic primary central nervous system (CNS) tumors or with intracranial metastases (excluding primary CNS tumors that may be eligible for enrollment as part of Cohort 2 e.g., NF-2 deficient meningioma) a. Subjects with leptomeningeal metastases are excluded 2. Uncontrolled or life-threatening symptomatic concomitant disease 3. Clinically significant cardiovascular disease as defined in the protocol 4. Women who are pregnant or breastfeeding 5. Subjects who are unable to swallow or retain oral medication 6. Prior treatment/exposure to YAP/TAZ/TEAD inhibitors 7. Other inclusion/exclusion criteria may apply |
Country | Name | City | State |
---|---|---|---|
United Kingdom | University Hospitals of Leicester NHS Trust | Leicester | England |
United Kingdom | The Royal Marsden Hospital | London | England |
United States | Massachusetts General Hospital | Boston | Massachusetts |
United States | The University of Chicago | Chicago | Illinois |
United States | Start Midwest | Grand Rapids | Michigan |
United States | MD Anderson Cancer Center | Houston | Texas |
United States | Sarah Cannon Research Institute | Nashville | Tennessee |
United States | Memorial Sloan Kettering Cancer Center | New York | New York |
United States | Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital | Philadelphia | Pennsylvania |
United States | University of Pennsylvania Abramson Cancer Center | Philadelphia | Pennsylvania |
United States | Next Oncology | San Antonio | Texas |
Lead Sponsor | Collaborator |
---|---|
Ikena Oncology |
United States, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety and tolerability of IK-930 | The frequency and severity, incidence of treatment-emergent and treatment-related adverse events using NCI-CTCAE v5.0 | Through study completion, an average of 36 months | |
Primary | Occurrence of Dose Limiting Toxicity during first treatment cycle | Approximately 1 year | ||
Primary | RP2D and/or MTD of IK-930 | Define the recommended phase 2 dose (RP2D) and/or MTD of IK-930 | Approximately 1 year | |
Secondary | Antitumor activity per RECIST 1.1: Disease control rate (DCR) of IK-930 as a single agent | Through study completion, average of 36 months | ||
Secondary | Antitumor activity per RECIST 1.1: Time to response (TTR) of IK-930 as a single agent | Through study completion, average of 36 months | ||
Secondary | Antitumor activity per RECIST 1.1: Duration of response (DOR) of IK-930 as a single agent | Through study completion, average of 36 months | ||
Secondary | Antitumor activity per RECIST 1.1: Objective response rate (ORR) of IK-930 as a single agent | Through study completion, average of 36 months | ||
Secondary | Antitumor activity: Median progression-free survival (PFS) of IK-930 as a single agent | Through study completion, average of 36 months | ||
Secondary | Antitumor activity: Median overall survival (OS) of IK-930 as a single agent | Through study completion, average of 36 months | ||
Secondary | Pharmacokinetics of IK-930: half-life (t1/2) | Approximately 1 year | ||
Secondary | Pharmacokinetics of IK-930: Area Under the Curve (AUC) | Approximately 1 year | ||
Secondary | Pharmacokinetics of IK-930: Maximum Plasma Concentration (Cmax) | Approximately 1 year | ||
Secondary | Pharmacokinetics of IK-930: Minimum Plasma Concentration (Cmin) | Approximately 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05580991 -
Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
Active, not recruiting |
NCT02846038 -
Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
|
||
Recruiting |
NCT05159388 -
A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181854 -
Randomized Controlled Trial of Integrated Early Palliative Care
|
N/A | |
Recruiting |
NCT05981703 -
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06014502 -
Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04107311 -
Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients
|
||
Active, not recruiting |
NCT04078152 -
Durvalumab Long-Term Safety and Efficacy Study
|
Phase 4 | |
Completed |
NCT02250157 -
A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies
|
Phase 1 | |
Recruiting |
NCT05566574 -
A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03943004 -
Trial of DFP-14927 in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06036836 -
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
|
Phase 2 | |
Recruiting |
NCT05525858 -
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
|
||
Recruiting |
NCT05798546 -
Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)
|
Phase 1 | |
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT00479128 -
Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04143789 -
Evaluation of AP-002 in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04550663 -
NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors
|
Phase 1 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 |